التفاصيل البيبلوغرافية
| العنوان: |
Nightstar posts early-phase data on retinal gene therapy. |
| المصدر: |
FierceBiotech; 9/24/2018, pN.PAG-N.PAG, 1p |
| مصطلحات موضوعية: |
RETINAL diseases, RETINITIS pigmentosa, X-linked genetic disorders, GUANOSINE triphosphatase regulation, GENE therapy, THERAPEUTICS |
| الشركة/الكيان: |
NIGHTSTARX Ltd. |
| مستخلص: |
Nightstar Therapeutics has presented early clinical data on its gene therapy treatment for X-linked retinitis pigmentosa. Around half of the patients in higher-doses cohorts experienced vision improvements, encouraging Nightstar to move NSR-RPGR into the larger phase 2 portion of the trial. [ABSTRACT FROM AUTHOR] |
|
Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
